A blood sample was drawn from each participant after an overnight (≥12 h) fast. Serum total cholesterol and triglycerides were determined enzymatically (Determiner L TG II; Kyowa Medex Co., Ltd., Tokyo, Japan). Serum high-density lipoprotein cholesterol was measured by selective inhibition method (MetaboLead HDL-C; Kyowa Medex Co., Ltd.). Serum low-density lipoprotein cholesterol was estimated according to the Friedewald equation (total cholesterol [mg/dL] − high-density lipoprotein cholesterol [mg/dL] – triglyceride [mg/dL]/5).21 (link) Blood glucose was assayed by hexokinase-G-6-PDH method (L-Type Glu 2; Wako Pure Chemical Industries, Ltd., Osaka, Japan), and insulin was measured by electrochemiluminescence immunoassay method (ECLusys Insulin; Roche Diagnostics, Tokyo, Japan). Glycated hemoglobin A (HbA1c) was determined by latex agglutination method (Determiner L HbA1c; Kyowa Medex Co., Ltd.). Venous blood was assayed by an independent laboratory (Kotobiken Medical Laboratories, Ibaraki, Japan).
Eclusys insulin
Manufactured by Roche
Sourced in Japan
The ECLusys Insulin is a laboratory equipment product designed for the detection and measurement of insulin levels. It utilizes an electrochemiluminescence (ECL) technique to accurately quantify insulin concentrations in biological samples. The core function of the ECLusys Insulin is to provide reliable and precise insulin analysis, which is essential for various clinical and research applications.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using eclusys insulin
1
Lipid and Glucose Biomarker Measurement
2
Oral Glucose Tolerance Test Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
After the baseline blood sampling, a standard 75-g OGTT was performed [17] , and serum samples for measuring glucose and immunoreactive insulin (IRI) were obtained at 0 min, 30 min, 60 min, 90 min, and 120 min after the glucose loading. Serum IRI levels were measured using an enzyme immunoassay (LS "Eiken" Insulin; Eiken Chemical Co., Ltd., Tokyo, Japan) between January 2005 and June 2006, using a chemiluminescent immunoassay (CLEIA) (Lumipulse Presto Insulin; Fujirebio, Inc., Tokyo, Japan) between June 2006 and March 2012, and using an electro-chemiluminescent immunoassay (ECLIA) (ECLusys Insulin; Roche Diagnostics, Basel, Switzerland) between April 2012 and December 2016. The results of the OGTT were defined as normal glucose tolerance (NGT), impaired fasting glucose (IFG), IGT, or DM according to the Japan Diabetes Society guidelines [15] . Plasma glycated hemoglobin (HbA1c) levels were reported in National Glycohemoglobin Standardization Program units and were measured using high-performance liquid chromatography (ADAMS A1c; Arkray, Inc., Tokyo, Japan).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!